Clinical Pathways Search Results

The PICU Asthma Pathway provides guidance for the care of patients with severe asthma exacerbation requiring ICU care.

This pathway provides guidance for identifying neonates symptomatic at or near the time of birth from Hypoxic-Ischemic Encephalopathy (HIE) who may be eligible whole body cooling.

The penicillin drug allergy pathway is meant to guide providers in assessing whether patients with a reported or labeled penicillin drug allergy should avoid penicillin, remove the allergy label, or refer to an allergist for skin testing or oral drug challenge.

Inpatient Clinical Pathway to standardize the process to screen for pulmonary hypertension in infants with Bronchopulmonary Dysplasia (BPD). BPD remains a major source of morbidity and mortality for extremely low birth weight infants.

Clinical Pathway for Inpatient Recommendations for SARS-CoV-2 Testing provides guidance for the evaluation and care of patients with suspected coronavirus (SARS-CoV-2).

This pathway should be used to guide the care of children ages 2-18 with known or suspected diagnosis of asthma.

This pathway guides the care of children who present with onset of flaccid weakness in one or more extremities +/- bulbar/cranial nerve findings without other clear cause. 

The PICU central diabetes insipidus pathway provides guidance for the care of patients with known or suspected central diabetes insipidus requiring ICU care.

The unprovoked seizure clinical pathway outlines the steps to standardize the ED clinical assessment, evaluation and recommend Neurology follow-up for healthy children presenting with new onset unprovoked seizure(s).

This pathway guides the ED and inpatient care for patients of any age with Genetically confirmed, Primary (Definite) Mitochondrial Disease or Suspected Mitochondrial Disease.